$0.00
These stories examined how the FDA approved cancer and diabetes drugs over the last decade. It found that in 74% of cancer drug approvals and all diabetes drug approvals, the decision to allow the drugs on the market was based on surrogate measures of effectiveness such CT scans or blood tests rather than real clinical outcomes such as improved survival or reductions in heart attacks, strokes or blindness.
